SRANKL (AA 70 – 244) protein (His tag)

Details for Product No. ABIN1112027, Supplier: Log in to see
Protein Name
Protein Characteristics
AA 70 – 244
Protein Type
Purification tag / Conjugate
His tag
Cell Culture (CC), Immunogen (Imm), Western Blotting (WB)
Log in to see
Supplier Product No.
Log in to see
Specificity Serological Identification: The protein was electrophoresed under reducing condition on a 15 % SDS-polyacrylamide gel, transferred by electro blotting to a NC membrane and visualized by immune-detection with specific RANKL antibody.
Characteristics Human recombinant protein expressed in Nicotiana benthamiana. Recombinant human Receptor activator of nuclear factor kappa-B ligand (sRANK-ligand) contains a 10-His tag at the N-terminal end, is produced by transient expression in non-transgenic plants. This product contains no animal-derived components or impurities. Animal free product.
Ext. Coeff. Abs (280nm) 0.1 % (=1g/l): E 0.1 % (1g/L) = 1.678 (A 280 nm)
p.I.: 6,82
Biological Activity: The specific activity is determined by the dose-dependent stimulation of IL-8 production in human PBMC. Activity results may vary with PBMC donors.
Biological Activity ng/ml: Human PBMC stimulated with 10 ng/ml of Human recombinant sRANKL increases in three times the basal production of IL-8.
Purification sequential chromatography (FPLC)
Purity > 97 % by SDS-PAGE gel
Endotoxin Level < 0.04 EU/µg protein (LAL method)
Background Synonyms: Tumor necrosis factor ligand superfamily member 11 (TNFSF11), Osteoprotegerin ligand (OPGL), TNF-related activation-induced cytokine (TRANCE)
Recombinant human RANKL is a member of TNF super family, a cytokine that play a central role in bone remodelling and disorders of mineral metabolism. It was shown to be a dendritic cell survival factor, T-cell activator and osteoclast regulator because RANKL mediates the osteoclast differentiation, survival and activation. Native RANKL is a type II trans-membrane protein with an extracellular binding domain that interacts with RANK and OPG receptors. OPG protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from binding to its receptor, RANK. Thus, RANKL/OPG ratio became an important determinant of bone mass and skeletal integrity. In addition, this protein was shown to activate anti-apoptotic kinase AKT/PKB through a signalling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TREAF). Recent findings shown that OPG/RANK/RANKL system has been identifies as a possible mediator of arterial calcification suggesting common links between osteoporosis and vascular diseases.
Molecular Weight 21.1 kDa
Restrictions For Research Use only
Format Lyophilized
Reconstitution Lyophilized protein should be reconstituted in water following instructions of batch Quality Control sheet. At higher concentrations the solubility may be reduced and multimers generated. Optimal concentration should be determined for specific application and cell lines.
Buffer 10 mM Phosphate Potasium buffer pH 8 and 0.2 M NaCl
Handling Advice Reconstituted protein should be stored in working aliquots at -20 °C. Repeated freezing and thawing is not recommended.
Storage 4 °C
Supplier Images
 image for SRANKL (AA 70 – 244) protein (His tag) (ABIN1112027) SDS-PAGE and Western blot analysis of human recombinant sRANKL. Lane MWM: molecular w...
Product cited in: DAmelio, Isaia, Isaia: "The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease." in: Journal of endocrinological investigation, Vol. 32, Issue 4 Suppl, pp. 6-9, 2009 (PubMed).

Takahashi, Udagawa, Suda: "A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function." in: Biochemical and biophysical research communications, Vol. 256, Issue 3, pp. 449-55, 1999 (PubMed).

Suda, Takahashi, Udagawa, Jimi, Gillespie, Martin: "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families." in: Endocrine reviews, Vol. 20, Issue 3, pp. 345-57, 1999 (PubMed).

Yasuda, Shima, Nakagawa, Yamaguchi, Kinosaki, Mochizuki, Tomoyasu, Yano, Goto, Murakami, Tsuda, Morinaga, Higashio, Udagawa, Takahashi, Suda: "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, Issue 7, pp. 3597-602, 1998 (PubMed).

Background publications Anderson, Maraskovsky, Billingsley, Dougall, Tometsko, Roux, Teepe, DuBose, Cosman, Galibert: "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function." in: Nature, Vol. 390, Issue 6656, pp. 175-9, 1997 (PubMed).

Did you look for something else?